European Commission at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
European Commission takes part in 2 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on EU regulatory policy for medicines. They cover regulatory incentives and market exclusivity as levers for new medicines, and the route to regulatory acceptance for new approach methodologies that model human biology.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
European Commission Brussels, Belgium | |
Executive body of the European Union, proposing legislation and running EU programmes, including health, medicines and research policy. | Panel Tue Nov 10 09:00–09:45 Accelerating Innovation and Market Exclusivity Through Regulatory Incentives How updated EU drug laws and the Biotech Act change how long new medicines are shielded from competing copies, compared with rules elsewhere. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Instantly find 20 buyers from European Commission
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction